Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFMBZ4)

Drug Name

Zanamivir Drug Info

Synonyms

zanamivir; 139110-80-8; Relenza; 4-Guanidino-Neu5Ac2en; GANA; Zanamavir; MODIFIED SIALIC ACID; GG167; UNII-L6O3XI777I; GG 167; GR-121167X; Zanamivir (Relenza); Relenza (TN); 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid; GR 121167X; CHEMBL222813; L6O3XI777I; ZMR; CHEBI:50663; GANA (inhibitor); 5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid; GNA; AK163166; GG-167; DSSTox_CID_3749; DSSTox_RID_77184; DSSTox_GSID_23749; Zanamivir [USAN:INN:BAN]; HSDB 7437; C12H20N4O7; GANA; Zanamivir hydrate; GR121167X; Zanamivir (USAN/INN); (2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid; 4-Guanidino-NeueAc2en; 5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid; ZNV; 4-guanidino-Neu5Ac2en; BAC-zanamivir

Indication

Disease Entry	ICD 11	Status	REF
Influenza	1E30-1E32	Approved	[1]
Influenza virus infection	1E30-1E32	Approved	[2]
Severe acute respiratory syndrome (SARS)	1D65	Investigative	[3]

Therapeutic Class

Antiviral Agents

Cross-matching ID

PubChem CID: 60855
ChEBI ID: CHEBI:50663
CAS Number: CAS 139110-80-8
TTD Drug ID: DMFMBZ4
VARIDT Drug ID: DR00960

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Influenza Neuraminidase (Influ NA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oseltamivir	DMGO72P	Influenza	1E30-1E32	Approved	[4]
Peramivir	DMNXY5K	Influenza virus infection	1E30-1E32	Approved	[5]
UX-001	DMD2O0L	Hereditary inclusion body myositis	4A41.2	Phase 3	[6]
CS-8958	DM4CSDH	Influenza virus infection	1E30-1E32	Phase 3	[5]
DAS-181	DM0Y8JP	Influenza virus infection	1E30-1E32	Phase 2	[7]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[6]
GS-3435	DMV7JC6	Influenza virus infection	1E30-1E32	Terminated	[8]
BCX-140	DMBJERO	Influenza virus infection	1E30-1E32	Terminated	[9]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[6]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Influenza Neuraminidase (Influ NA)	TT50QJ3	NRAM_I33A0	Inhibitor	[4]

------------------------------------------------------------------------------------

References

1	Zanamivir FDA Label
2	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 021036
3	Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004 Apr;10(4):581-6. doi: 10.3201/eid1004.030458.
4	Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102.
5	Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13.
6	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7	Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838.
8	US patent application no. 2010,0081,713, Compositions and methods for treating viral infections.
9	CN patent application no. 104447481, Benzoic acid thiourea anti-influenza virus compounds as well as preparation method and use thereof.